While full GR agonists enable suppression of pro-inflammatory immune responses (e.g., TNF-α expression), they may also result in unwanted adverse effects such as hyperglycemia, skin atrophy, or bone resorption. This evidence concerns the gene NR3C1 and skin atrophy.